Last reviewed · How we verify
Extended-Release Buprenorphine Injection
Extended-Release Buprenorphine Injection is a Small molecule drug developed by NYU Langone Health. It is currently FDA-approved. Also known as: Sublocade, Medication for Opioid Use Disorder, CAM2038, XR-BUP.
Extended-Release Buprenorphine Injection is used to treat opioid-related disorders, including opioid use disorder, and is classified as a mu opioid receptor agonist. It is a small molecule that acts as an agonist at the mu-type opioid receptor, which is involved in the treatment of opioid addiction.
At a glance
| Generic name | Extended-Release Buprenorphine Injection |
|---|---|
| Also known as | Sublocade, Medication for Opioid Use Disorder, CAM2038, XR-BUP, RBP-6000 |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use (EARLY_PHASE1)
- Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial (PHASE4)
- Combined Injectable Treatment for HIV and OUD (PHASE2)
- The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions (NA)
- Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended-Release Buprenorphine Injection CI brief — competitive landscape report
- Extended-Release Buprenorphine Injection updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Extended-Release Buprenorphine Injection
What is Extended-Release Buprenorphine Injection?
Who makes Extended-Release Buprenorphine Injection?
Is Extended-Release Buprenorphine Injection also known as anything else?
What development phase is Extended-Release Buprenorphine Injection in?
Related
- Manufacturer: NYU Langone Health — full pipeline
- Also known as: Sublocade, Medication for Opioid Use Disorder, CAM2038, XR-BUP, RBP-6000
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing